[Use of alpha-adrenoblockers in therapy of benign prostatic hyperplasia in patients with arterial hypertension].
To compare efficacy and tolerance of tonocardin (doxazosin) and omnik (tamsulosin) in the treatment of benign prostatic hyperplasia (BPH) in hypertensive patients. Group 1 patients (n = 115, age 44-81 years) with BPH and mild or moderate arterial hypertension (AH) treated with one antihypertensive drug (ACE inhibitor--48, calcium antagonist--26, beta-blocker--22, diuretic--19) were given tonocardin in a single daily dose from 1 to 4 mg for 12 weeks. Group 2 patients (n = 30, age 67-81 years) with BPH and severe AH treated with two antihypertensive drugs and more were given omnik in a single daily dose 0.4 mg for 12 weeks. In group 1, tonocardin treatment resulted in lowering of a total symptoms score by IPSS scale from 17.5 +/- 3.6 to 14.7 +/- 1.3 points, of quality of life from 4.3 +/- 0.7 to 3.9 +/- 0.3, in a rise of maximal velocity of urine flow (Qmax) from 7.8 +/- 1.2 to 9.4 +/- 0.6 ml/s; residual urine (R) reduced from 112.4 +/- 8.6 to 64.5 +/- 10.2 ml). Systolic arterial pressure went down from 150.5 +/- 13 to 139.8 +/- 13.3 mm Hg, diastolic pressure fell from 86.9 +/- 6.1 to 80.8 +/- 7.1 mm Hg. In group 2, omnik resulted in IPSS scale points lowering from 17.7 +/- 3.5 to 15 +/- 1.1, QOL from 4.5 +/- 0.2 to 3.8 +/- 0.2, Qmax from 7.4 +/- 1.1 to 9.2 +/- 0.5 ml/s, R from 107.5 +/- 12.7 to 63.4 +/- 9.7 ml. Arterial pressure did not change much. Tonocardin and omnik are effective and safe not only in the treatment of BPH but also of BPH combination with AH.